Trial · NCT00890656
Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage
NCT00890656, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2011-08-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage. Trials, record NCT00890656. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00890656
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage
- NCT number
- NCT00890656
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 90 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide (CTX), Vincristine, Doxorubicin, Decadron, G-CSF, Methotrexate (MTX), Ara-C, Pegaspargase
- First posted
- 2009-04-30
- Last updated
- 2012-02-20
- Results first posted
- 2011-08-23
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Complete Remission | Response evaluated following first course at 14 -21 days and 1-2 weeks later to confirm response status (or at the time of hematologic recovery) and with visits every 2-3 courses. | Complete remission (CR) required a marrow with ≤ 5% blasts in a normo- or hypercellular marrow with an absolute neutrophil count (ANC) of ≥ 1 \* 10\^9/L and a platelet count of ≥ 100 \* 10\^9/L with complete resolution of all sites of extramedullary disease required. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Complete Remission | Response evaluated following first course at 14 -21 days and 1-2 weeks later to confirm response status (or at the time of hematologic recovery) and with visits every 2-3 courses. | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Complete Remission | Augmented Hyper-CVAD | 41 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Augmented Hyper-CVAD | 90 | |
| Overall Study | COMPLETED | Augmented Hyper-CVAD | 90 | |
| Overall Study | NOT COMPLETED | Augmented Hyper-CVAD | 0 |
Source ClinicalTrials.gov
Adverse events23
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea/Vomiting | Gastrointestinal disorders | Augmented Hyper-CVAD | 32 | 90 | 32 |
| other | Diarrhea | Gastrointestinal disorders | Augmented Hyper-CVAD | 23 | 90 | 23 |
| other | Neuropathy | Nervous system disorders | Augmented Hyper-CVAD | 13 | 90 | 13 |
| other | hyperglycemia | Endocrine disorders | Augmented Hyper-CVAD | 17 | 90 | 17 |
| other | Elevated liver function tests | Hepatobiliary disorders | Augmented Hyper-CVAD | 29 | 90 | 29 |
| other | Pain | General disorders | Augmented Hyper-CVAD | 5 | 90 | 5 |
| other | Mucositis | Gastrointestinal disorders | Augmented Hyper-CVAD | 19 | 90 | 19 |
| serious | Neutropenic fever | Infections and infestations | Augmented Hyper-CVAD | 8 | 90 | 8 |
| serious | Death | General disorders | Augmented Hyper-CVAD | 9 | 90 | 9 |
| serious | Infection | Infections and infestations | Augmented Hyper-CVAD | 21 | 90 | 21 |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Augmented Hyper-CVAD | ||
| Total, other adverse events | Augmented Hyper-CVAD | 57 | 90 |
| Total, serious adverse events | Augmented Hyper-CVAD | 33 | 90 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00890656
GET https://conductscience.org/api/trials/v1/NCT00890656/events?page=2